Update of the management of rheumatoid arthritis in pregnancy

References

• Carmona L, Cross M, Williams B, Lassere M, March L. Rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol.24(6), 733–745 (2010).
   PubMed Web of Science ®Google Scholar
• Symmons D, Turner G, Webb R et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford)41(7), 793–800 (2002).
   PubMed Web of Science ®Google Scholar
• Golding A, Haque UJ, Giles JT. Rheumatoid arthritis and reproduction. Rheum. Dis. Clin. North. Am.33(2), 319–343 (2007).
   PubMed Web of Science ®Google Scholar
• Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum.54(3), 899–907 (2006).
   PubMed Web of Science ®Google Scholar
• Chakravarty EF. Rheumatoid arthritis and pregnancy: beyond smaller and preterm babies. Arthritis Rheum.63(6), 1469–1471 (2011).
   PubMedGoogle Scholar
• Wallenius M, Skomsvoll JF, Irgens LM et al. Pregnancy and delivery in women with chronic inflammatory arthritides with a specific focus on first birth. Arthritis Rheum.63(6), 1534–1542 (2011).
   PubMed Web of Science ®Google Scholar
• Areskoug-Josefsson K, Oberg U. A literature review of the sexual health of women with rheumatoid arthritis. Musculoskeletal Care7(4), 219–226 (2009).
   PubMedGoogle Scholar
• van Berlo WT, van de Wiel HB, Taal E, Rasker JJ, Weijmar Schultz WC, van Rijswijk MH. Sexual functioning of people with rheumatoid arthritis: a multicenter study. Clin. Rheumatol.26(1), 30–38 (2007).
   PubMed Web of Science ®Google Scholar
• Jawaheer D, Zhu JL, Nohr EA, Olsen J. Time to pregnancy among women with rheumatoid arthritis. Arthritis Rheum.63(6), 1517–1521 (2011).
   PubMedGoogle Scholar
• Østensen M. Counselling women with rheumatic disease – how many children are desirable? Scand. J. Rheumatol.20(2), 121–126 (1991).
   PubMed Web of Science ®Google Scholar
• Mendonca LLF, Khamashta MA, Nelson-Piercy C, Hunt BJ, Hughes GRV. Non-steroidal anti-inflammatory drugs as a possible cause for reversible infertility. Rheumatology (Oxford)39, 880–882 (2000).
   PubMed Web of Science ®Google Scholar
• Li DK, Liu L, Odouli R. Exposure of non-steroidal anti-inflammatory drugs during pregnancy and the risk of miscarraige: population-based cohort study. BMJ327, 368–378 (2001).
   Google Scholar
• Flaisler F, Hedon B, Sany J, Combe B. A study of ovarian fucntion in rheumatoid arthritis. Rev. Rheum. Engl. Ed.62, 549–554 (1995).
   PubMedGoogle Scholar
• Katz PP. Childbearing decisions and family size among women with rheumatoid arthritis. Arthritis Rheum.55(2), 217–223 (2006).
   PubMed Web of Science ®Google Scholar
• Camacho EM, Harrison M, Farragher TM et al. Parity, time since last live birth and long-term functional outcome: a study of women participating in the Norfolk Arthritis Register. Ann. Rheum. Dis.70(4), 642–645 (2011).
   PubMedGoogle Scholar
• Forger F, Østensen M, Schumacher A, Villiger PM. Impact of pregnancy on health related quality of life evaluated prospectively in pregnant women with rheumatic diseases by the SF-36 health survey. Ann. Rheum. Dis.64(10), 1494–1499 (2005).
   PubMed Web of Science ®Google Scholar
• Hench P. The ameliorating effect of pregnancy on chronic atrophic (infectious rheumatoid) arthritis, fibrositis, and intermittent hydrarthrosis. Mayo Clin. Proc.13, 161–180 (1938).
   Google Scholar
• Forger F, Marcoli N, Gadola S, Moller B, Villiger PM, Ostensen M. Pregnancy induces numerical and functional changes of CD4+CD25 high regulatory T cells in patients with rheumatoid arthritis. Ann. Rheum. Dis.67(7), 984–990 (2008).
   PubMed Web of Science ®Google Scholar
• Straub RH. The complex role of estrogens in inflammation. Endocr. Rev.28(5), 521–574 (2007).
   PubMed Web of Science ®Google Scholar
• Clark DA, Arck PC, Chaouat G. Why did your mother reject you? Immunogenetic determinants of the response to environmental selective pressure expressed at the uterine level. Am. J. Reprod. Immunol.41(1), 5–22 (1999).
   PubMed Web of Science ®Google Scholar
• Straub RH, Buttgereit F, Cutolo M. Benefits of pregnancy in inflammatory arthritis. Ann. Rheum. Dis.64, 801–803 (2005).
   PubMed Web of Science ®Google Scholar
• Østensen M, Forger F, Nelson JL, Schuhmacher A, Hebisch G, Villiger PM. Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum. Ann. Rheum. Dis.64(6), 839–844 (2005).
   PubMed Web of Science ®Google Scholar
• Østensen M, Villiger PM. Immunology of pregnancy – pregnancy as a remission inducing agent in rheumatoid arthritis. Transpl. Immunol.9, 155–160 (2002).
   PubMedGoogle Scholar
• Alavi A, Arden N, Spector TD, Axford JS. Immunoglobulin G glycosylation and clinical outcome in rheumatoid arthritis during pregnancy. J. Rheumatol.27(6), 1379–1385 (2000).
   PubMedGoogle Scholar
• Kasukawa R, Ohara M, Yoshida H, Yoshida T. Pregnancy-associated a2-glycoprotein in rheumatoid arthritis. Int. Arch. Allergy Appl. Immunol.58(1), 67–74 (1979).
   PubMedGoogle Scholar
• Nelson JL, Hughes KA, Smith AG, Nisperos BB, Branchaud AM, Hansen JA. Maternal-fetal disparity in HLA class II alloantigens and pregnancy-induced amelioraton of rheumatoid arthritis. N. Eng. J. Med.329, 466–471 (1993).
   PubMed Web of Science ®Google Scholar
• Barrett JH, Brennan P, Fiddler M, Silman AJ. Does rhematoid arthritis remit during pregnancy and relapse postpartum? Resuls from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum.42(6), 1219–1227 (1999).
   PubMed Web of Science ®Google Scholar
• de Man YA, Dolhain RJ, van de Geijn FE, Willemsen SP, Hazes JM. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum.59(9), 1241–1248 (2008).
   PubMed Web of Science ®Google Scholar
• de Man YA, Bakker-Jonges LE, Goorbergh CM et al. Women with rheumatoid arthritis negative for anti-cyclic citrullinated peptide and rheumatoid factor are more likely to improve during pregnancy, whereas in autoantibody-positive women autoantibody levels are not influenced by pregnancy. Ann. Rheum. Dis.69(2), 420–423 (2010).
   PubMed Web of Science ®Google Scholar
• Oka M. Effect of pregnancy on the onset and course of rheumatoid arthritis. Ann. Rheum. Dis.12(3), 227–229 (1953).
   PubMed Web of Science ®Google Scholar
• Bowden AP, Barrett JH, Fallow W, Silman AJ. Women with inflammatory polyarthritis have babies of lower birth weight. J. Rheumatol.28(2), 355–359 (2001).
   PubMed Web of Science ®Google Scholar
• Skomsvoll JF, Ostensen M, Irgens LM, Baste V. Pregnancy complications and delivery practice in women with connective tissue diseases and inflammatory rheumatic disease in Norway. Acta. Obstet. Gynecol. Scand.79, 490–495 (2000).
   PubMedGoogle Scholar
• Wolfberg AJ, Lee-Parritz A, Peller AJ, Lieberman ES. Association of rheumatologic disease with preeclampsia. Obstet. Gynecology103(6), 1190–1193 (2004).
   PubMed Web of Science ®Google Scholar
• Lin HC, Chen SF, Chen YH. Increased risk of adverse pregnancy outcomes in women with rheumatoid arthritis: a nationwide population-based study. Ann. Rheum. Dis.69(4), 715–717 (2010).
   PubMed Web of Science ®Google Scholar
• Skomsvoll JF, Ostensen M, Irgens LM, Baste V. Perinatal outcomes in pregnancies of women with connective tissue disease and inflammatory rheumatic disease in Norway. Scand. J. Rheumatol.28, 352–356 (1999).
   PubMedGoogle Scholar
• Reed SD, Vollan TA, Svec MA. Pregnancy outcomes in women with rheumatoid arthritis in Washington State. Matern. Child Health J.10(4), 361–366 (2006).
   PubMed Web of Science ®Google Scholar
• Nørgaard M, Larsson H, Pedersen L et al. Rheumatoid arthritis and birth outcomes: a Danish and Swedish nationwide prevalence study. J. Intern. Med.268(4), 329–337 (2010).
   PubMed Web of Science ®Google Scholar
• Bramham K, Soh MC, Nelson Piercy C. Pregnancy and renal outcomes in lupus nephritis: an update, and guide to management. Lupus (2011) (In Press).
   Google Scholar
• Østensen M, Khamashta M, Lockshin M et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res. Ther.8(3), 209 (2006).
   PubMed Web of Science ®Google Scholar
• Van den Veyver IB, Moise KJ Jr, Ou CN, Carpenter RJ Jr. The effect of gestational age and fetal indomethacin levels on the incidence of constriction of the fetal ductus arteriosus. Obstet. Gynecol.82(4 Pt 1), 500–503 (1993).
   PubMedGoogle Scholar
• Alano MA, Ngougmna E, Ostrea EM Jr, Konduri GG. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics107(3), 519–523 (2001).
   PubMed Web of Science ®Google Scholar
• Østensen M, Forger F. Management of RA medications in pregnant patients. Nat. Rev. Rheumatol.5(7), 382–390 (2009).
   PubMed Web of Science ®Google Scholar
• Hickok DE, Hollenbach KA, Reilley SF, Nyberg DA. The association between decreased amniotic fluid volume and treatment with nonsteroidal anti-inflammatory agents for preterm labor. Am. J. Obstet. Gynecol.160(6), 1525–1530; discussion 1530–1521 (1989).
   PubMed Web of Science ®Google Scholar
• Kaplan BS, Restaino I, Raval DS, Gottlieb RP, Bernstein J. Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents. Pediatr. Nephrol.8, 700–704 (1994).
   PubMedGoogle Scholar
• Pall M, Friden BE, Brannstrom M. Induction of delayed follicular rupture in human by selective COX-2 inhibitor rofecoxib: a randomized double blind study. Hum. Reprod.16, 1323–1328 (2001).
   PubMed Web of Science ®Google Scholar
• Burdan F, Dudka J, Szumilo J, Korobowicz A, Klepacz L. Prenatal effects of DuP-697 – the irreversible, highly selective cyclooxygenase-2 inhibitor. Reprod. Toxicol.17(4), 413–419 (2003).
   PubMedGoogle Scholar
• Cappon GD, Cook JC, Hurtt ME. Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. Birth Defects Res. B Dev. Reprod. Toxicol.68(1), 47–56 (2003).
   PubMed Web of Science ®Google Scholar
• Stika CS, Gross GA, Leguizamon G et al. A prospective randomized safety trial of celecoxib for treatment of preterm labor. Am. J. Obstet. Gynecol.187(3), 653–660 (2002).
   PubMed Web of Science ®Google Scholar
• Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy and lactation. Arch. Internal Med.160, 610–619 (2000).
   PubMed Web of Science ®Google Scholar
• Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst. Rev.2, CD004659 (2007).
   PubMed Web of Science ®Google Scholar
• Kozer E, Costei AM, Boskovic R, Nulman I, Nikfar S, Koren G. Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. Birth Defects Res. B Dev. Reprod. Toxicol.68(1), 70–84 (2003).
   PubMedGoogle Scholar
• Di Sessa TG, Moretti ML, Khoury A, Pulliam DA, Arheart KL, Sibai BM. Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am. J. Obstet. Gynecol.171(4), 892–900 (1994).
   PubMed Web of Science ®Google Scholar
• de Swiet M, Redman CW. Aspirin, extradural anaesthesia and the MRC Collaborative Low-dose Aspirin Study in Pregnancy (CLASP). Br. J. Anaesth.69(1), 109–110 (1992).
   PubMedGoogle Scholar
• Østensen M. Glucocorticoids in pregnant patients with rheumatoid arthritis. Z. Rheumatol59(Suppl. 2), II 70–74 (2000).
   PubMedGoogle Scholar
• Park-Wyllie L, Mazzotta P, Pastuszak A et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology62(6), 385–392 (2000).
   PubMedGoogle Scholar
• Pradat P, Robert-Gnansia E, Di Tanna GL et al. First trimester exposure to corticosteroids and oral clefts. Birth Defects Res. A Clin. Mol. Teratol.67, 968–970 (2003).
   PubMed Web of Science ®Google Scholar
• Hviid A, Molgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ183(7), 796–804 (2011).
   PubMed Web of Science ®Google Scholar
• Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am. J. Obstet. Gynecol.166(5), 1318–1323 (1992).
   PubMed Web of Science ®Google Scholar
• Czeizel AE. Birth weight, gestational age and medications during pregnancy. Int. J. Gynaecol. Obstet.60, 254–249 (1998).
   Google Scholar
• Sperber K, Hom C, Chao CP, Shapiro D, Ash J. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Int. J. Gynaecol. Obstet.7, 9 (2009).
   Google Scholar
• Motta M, Tincani A, Faden D et al. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J. Perinatol.25(2), 86–89 (2005).
   PubMedGoogle Scholar
• Klinger G, Morad Y, Westall CA et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet358(9284), 813–814 (2001).
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcomes in women with inflammatory bowel disease following exposure to 5-amniosalicylic acid drugs: a meta-analysis. Reprod. Toxicol.25, 271–275 (2008).
   PubMed Web of Science ®Google Scholar
• Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N. Engl. J. Med.343(22), 1608–1614 (2000).
   PubMed Web of Science ®Google Scholar
• Moody GA, Probert C, Jayanthi V, Mayberry JF. The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men and women with inflammatory bowel disease in Leicestershire. Int. J. Colorectal Dis.12(4), 220–224 (1997).
   PubMed Web of Science ®Google Scholar
• Lloyd ME, Carr M, McElhatton P, Hall GM, Hughes RA. The effects of methotrexate on pregnancy, fertility and lactation. Q. J. Med.92, 551–563 (1999).
   Google Scholar
• Østensen M. Management of early aggressive rheumatoid arthritis during pregnancy and lactation. Expert Opin. Pharmacother.10(9), 1469–1479 (2009).
   PubMed Web of Science ®Google Scholar
• Martínez Lopez JA, Loza E, Carmona L. Systematic reivew of the safety of methotrexate in rheumatoid arthritis regarding the reproducitve system (fertility, pregnancy and breastfeeding). Clin. Exp. Rheumatol.27(4), 678–684 (2009).
   PubMed Web of Science ®Google Scholar
• Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am. J. Med.88(6), 589–592 (1990).
   PubMed Web of Science ®Google Scholar
• Aviles A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin. Lymphoma2(3), 173–177 (2001).
   PubMedGoogle Scholar
• Dalrymple JM, Stamp LK, O’Donnell JL, Chapman PT, Zhang M, Barclay ML. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum.58(11), 3299–3308 (2008).
   PubMed Web of Science ®Google Scholar
• Gromnica-Ihle E, Kruger K. Use of methotrexate in young patients with respect to the reproductive system. Clin. Exp. Rheumatol.28(Suppl. 61), S80–S84 (2010).
   PubMed Web of Science ®Google Scholar
• Beghin D, Cournot MP, Vauzelle C, Elefant E. Paternal exposure to methotrexate and pregnancy outcomes. J. Rheumatol.38(4), 628–632 (2011).
   PubMed Web of Science ®Google Scholar
• Chakravarty K, McDonald H, Pullar T et al. BSR/BHPR guideline for disease-modifying antirheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology47(6), 924–925 (2008).
   PubMed Web of Science ®Google Scholar
• Johns DG, Rutherford LD, Leighton PC, Vogel CL. Secretion of methotrexate into human milk. Am. J. Obset. Gynecol.112, 978–980 (1972).
   PubMed Web of Science ®Google Scholar
• Fukushima R, Kanamori S, Hirashiba M et al. Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Reprod. Toxicol.24(3–4), 310–316 (2007).
   PubMed Web of Science ®Google Scholar
• Brent RL. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology63(2), 106–112 (2001).
   PubMedGoogle Scholar
• Chambers CD, Johnson DL, Robinson LK et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum.62(5), 1494–1503 (2010).
   PubMed Web of Science ®Google Scholar
• De Santis M, Straface G, Cavaliere A et al. Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome. Ann. Rheum. Dis.64, 1096–1097 (2005).
   PubMed Web of Science ®Google Scholar
• Almarzouqi M, Scarsbrook D, Klinkhoff A. Gold therapy in women planning pregnancy: outcomes in one center. J. Rheumatol.34(9), 1827–1831 (2007).
   PubMed Web of Science ®Google Scholar
• Tarp U, Graudal H. A followup study of children exposed to gold compounds in utero. Arthritis Rheum.28(2), 235–236 (1985).
   PubMedGoogle Scholar
• Myamoto T, Miyaji S, Horiuchi Y, Hara M, Ishihara K. Gold therapy in bronchial asthma – a special emphasis upon blood levels of gold and its teratogenecity. J. Jpn Soc. Internal Med.63, 1190–1197 (1974).
   PubMedGoogle Scholar
• Richards AJ. Transfer of gold from mother to fetus. Lancet1(8002), 99 (1977).
   PubMedGoogle Scholar
• Cohen DL, Orzel J, Taylor A. Infants of mothers receiving gold therapy. Arthritis Rheum.24(1), 104–105 (1981).
   PubMedGoogle Scholar
• American Academy of Pediatrics. Transfer of drugs and other chemicals into human breast milk. Pediatrics93(1), 137–150 (1994).
   PubMed Web of Science ®Google Scholar
• Østensen M, Skavdal K, Myklebust G, Tomasen Y, Aarbakke J. Excretion of gold into human breast milk. Eur. J. Clin. Pharmacol.31, 251–252 (1986).
   PubMed Web of Science ®Google Scholar
• Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J. Rheumatol.36(3), 635–641 (2009).
   PubMed Web of Science ®Google Scholar
• Koren G, Inoue M. Do tumour necrosis factor inhibitors cause malformations in humans? J. Rheumatol.36(3), 465–466 (2009).
   PubMed Web of Science ®Google Scholar
• Østensen M. Are TNF inhibitors safe in pregnancy? Nat. Rev. Rheumatol.5, 184–185 (2009).
   PubMed Web of Science ®Google Scholar
• Clowse ME. The use of anti-TNFα medications for rheumatologic disease in pregnancy. Int. J. Women’s Health2, 199–209 (2010).
   PubMedGoogle Scholar
• Winger EE, Reed JL. Was risk properly assessed in Carter et al.’s safety assessment of tumor necrosis factor antagonists during pregnancy? J. Rheumatol.36(9), 2122; author reply 2123 (2009).
   PubMedGoogle Scholar
• Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL. Concise report: anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis.70(5), 823–826 (2011).
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Listing J, Rau R et al. Pregnancy outcome after exposure to biologics: results from the German biologics register RABBITT Arthritis Rheum.56(Suppl.), S311 (2007).
   PubMedGoogle Scholar
• Vinet E, Pineau C, Gordon C, Clarke AE, Bernatsky S. Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum.61(5), 587–592 (2009).
   PubMed Web of Science ®Google Scholar
• Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin. Gastroenterol. Hepatol.4(10), 1255–1258 (2006).
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Terdiman JP, Church J. Infliximab levels in infants born to women with inflammatory bowel disease. Gastroenterology132(4 Suppl. 1), A144 (2007).
   Google Scholar
• Zelinkova Z, de Haar C, de Ridder L et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol. Ther.33(9), 1053–1058 (2011).
   PubMed Web of Science ®Google Scholar
• Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin. Gastroenterol. Hepatol.4(10), 1255–1258 (2006).
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Kane SV, Church JA, Vasiliauskas EA, Sandborn WJ, Dubinsky MC. The effect of maternal peripartum infliximab use on neonatal immune response. Gastroenterology134 (2008) (Abstract 69).
   Google Scholar
• Cheent K, Nolan J, Shariq S, Ciho L, Pal A, Arnold J. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s disease. J.Crohns Colitis4(5), 603–605 (2010).
   PubMed Web of Science ®Google Scholar
• Wolf D, Mahadevan U. Certolizumab pegol use in pregnancy: low levels detected in cord blood. From the ACR 2010 conference. Arthritis Rheum. (Suppl.) (2010) (Abstract 718).
   Google Scholar
• Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn’s disease before and after delivery. J. Clin. Gastroenterol.43(7), 613–616 (2009).
   PubMed Web of Science ®Google Scholar
• Djokanovic N, Klieger-Grossmann C, Pupco A, Koren G. Safety of infliximab use during pregnancy. Reprod. Toxicol.32(1), 93–97 (2011).
   PubMed Web of Science ®Google Scholar
• Murashima A, Watanabe N, Ozawa N, Saito H, Yamaguchi K. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant’s serum. Ann. Rheum. Dis.68(11), 1793–1794 (2008).
   Google Scholar
• Ben-Horin S, Yavzori M, Katz L et al. Adalimumab level in breast milk of a nursing mother. Clin. Gastroenterol. Hepatol.8, 475–476 (2010).
   PubMed Web of Science ®Google Scholar
• Klink DT, van Elburg RM, Schreurs MW, van Well GT. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin. Dev. Immunol.2008, 271363 (2008).
   PubMedGoogle Scholar
• Rituxan®, package insert. Gentech, San Francisco, CA, USA.
   Google Scholar
• Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood117(5), 1499–1506 (2011).
   PubMed Web of Science ®Google Scholar
• Pham T, Fautrel B, Gottenberg JE et al. Rituximab (MabThera) therapy and safety management. Clinical tool guide. Joint Bone Spine75(Suppl. 1), S1–S99 (2008).
   PubMedGoogle Scholar
• Ornoy A, Chen L, Silver RM, Miller RK. Maternal autoimmune diseases and immunologically induced embryonic and fetoplacental damage. Birth Defects Res. A Clin. Mol. Teratol.70(6), 371–381 (2004).
   PubMedGoogle Scholar
• Levy S, Fayez I, Taguchi N et al. Pregnancy outcomes following in utero exposure to bisphosphonates. Bone44(3), 428–430 (2009).
   PubMed Web of Science ®Google Scholar
• Angelberger S, Reinisch W, Messerschmidt A et al. Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. J. Crohns Colitis5(2), 95–100 (2011).
   PubMed Web of Science ®Google Scholar
• Motta M, Tincani A, Meroni PL, Cimaz R. Follow-up of children exposed antenatally to immunosuppressive drugs. Rheumatology47(Suppl. 3), 32–34 (2008).
   Google Scholar
• Motta M, Ciardelli L, Marconi M et al. Immune system development in infants born to mothers with autoimmune disease, exposed in utero to immunosuppressive agents. Am J. Perinatol.24(8), 441–447 (2007).
   PubMed Web of Science ®Google Scholar
• Nulman I, Sgro M, Barrera M, Chitayat D, Cairney J, Koren G. Long-term neurodevelopment of children exposed in utero to ciclosporin after maternal renal transplant. Paediatr. Drugs12(2), 113–122 (2010).
   PubMedGoogle Scholar
• Skomsvoll JF, Baste V, Irgens LM, Østensen M. The recurrence risk of adverse outcome in the second pregnancy in women with rheumatic disease. Obstet. Gynecol.100(6), 1196–1202 (2002).
   PubMedGoogle Scholar
• Arsenescu R, Arsenescu V, de Villiers WJ. TNF-alpha and the development of the neonatal immune system: implications for inhibitor use in pregnancy. Am. J. Gastroenterol.106(4), 559–562 (2011).
   PubMed Web of Science ®Google Scholar
• Jarnerot G, Andersen S, Esbjorner E, Sandstrom B, Brodersen R. Albumin reserve for binding of bilirubin in maternal and cord serum under treatment with sulphasalazine. Scand. J. Gastroenterol.16(8), 1049–1055 (1981).
   PubMed Web of Science ®Google Scholar
• Elliott AB, Chakravarty EF. Immunosuppressive medications during pregnancy and lactation in women with autoimmune diseases. Women’s Health6(3), 431–442 (2010).
   PubMedGoogle Scholar
• Cleary BJ, Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res. A Clin. Mol. Teratol.85, 647–654 (2009).
   PubMed Web of Science ®Google Scholar
• Sau A, Clarke S, Bass J, Kaiser A, Marinaki A, Nelson-Piercy C. Azathioprine and breastfeeding: is it safe? BJOG114(4), 498–501 (2007).
   PubMed Web of Science ®Google Scholar
• Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation71(8), 1051–1055 (2001).
   PubMed Web of Science ®Google Scholar
• Enns GM, Roeder E, Chan RT, Ali-Khan Catts Z, Cox VA, Golabi M. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? Am. J. Med. Genet.86(3), 237–241 (1999).
   PubMed Web of Science ®Google Scholar
• Clowse ME, Magder L, Petri M. Cyclophosphamide for lupus during pregnancy. Lupus14(8), 593–597 (2005).
   PubMed Web of Science ®Google Scholar
• Ornoy A, Wajnberg R, Diav-Citrin O. The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod. Toxicol.22(4), 578–579 (2006).
   PubMed Web of Science ®Google Scholar